Gensia

Tocagen appoints Wood VP, regulatory affairs and quality assurance

Friday, February 19, 2016

Tocagen, a clinical-stage, cancer-selective gene therapy company, has named John Wood vice president of regulatory affairs and quality assurance. Wood holds more than 20 years of regulatory affairs experience focusing on first-in-class drugs for diseases with high unmet need. While at IDEC Pharmaceuticals, he played a leading role, in close collaboration with Genentech, in the first regulatory approval of RITUXAN for the treatment of immune system B-cell malignancies.

[Read More]